Table III.

Binding capacity of GAD65, proinsulin, and IA-2 peptides containing the deduced DQA1*0102/DQB1*0602 peptide binding motif for DQA1*0102/DQB1*0602a

PeptideSequencebIC50 (μM)
IA-2(586–596)GVAGLLVALAV0.70
IA-2(499–509)MSSGSFINISV0.94
Insulin B(5–15)HLCGSHLVEAL1.7
GAD65(334–344)ATAGTTVYGAF1.7
GAD65(91–101)FLHATDLLPAC1.9
GAD65(396–406)KMMGVPLQCSA3.0
Proinsulin(11–21)LVEALYLVCGE5.8
IA-2(576–586)SVLLTLVALAG6.6
GAD65(116–126)NILLQYVVKSF12
IA-2(504–514)FINISVVGPAL13
IA-2(543-553)AQTGLQILQTG13
IA-2(544–554)QTGLQILQTGV23
IA-2(584–594)LAGVAGLLVAL31
Proinsulin(36–46)DLQVGQVELGG40
IA-2(379–389)VNVGADIKKTM48
GAD65(503–513)NVCFWYIPPSL58
IA-2(229–239)MVSVGPLPKAE62
IA-2(530–540)VTQQAGLVKSE64
GAD65(365–375)AAWGGGLLMSR70
GAD65 (86–96)DVNYAFLHATD90
IA-2(361–371)LTLLQLLPKGA>100
GAD65(378–388)KWKLSGVERAN>100
GAD65(526–536)LSKVAPVIKAR>100
IA-2(373–383)RNPGGVVNVGA>100
IA-2(335–345)LQRLAAVLAGY>100
  • a Binding was measured as described for the DQ0602 competition assay in Materials and Methods.

  • b The putative DQ0602 peptide binding motifs are shown in bold letters.